Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.

Ko SS, Jordan VC.

Expert Opin Pharmacother. 2011 Mar;12(4):657-74. doi: 10.1517/14656566.2011.557360. Epub 2011 Feb 7. Review. Retraction in: Expert Opin Pharmacother. 2012 May;13(7):1081.

2.

Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.

Lee WL, Chao HT, Cheng MH, Wang PH.

Maturitas. 2008 Jun 20;60(2):92-107. doi: 10.1016/j.maturitas.2008.04.009. Epub 2008 Jun 4. Review.

PMID:
18534794
3.

[Specific estrogen receptor modulators (SERMs)].

Trémollières F, Lopes P.

Presse Med. 2002 Sep 7;31(28):1323-8. Review. French.

PMID:
12355995
4.

[Which is the better choice, estrogen or SERMs in postmenopausal women?].

Shintani M.

Clin Calcium. 2004 Oct;14(10):105-10. Review. Japanese.

PMID:
15577140
5.

Recommendations for raloxifene use in daily clinical practice in the Swiss setting.

Lippuner K, Buchard PA, De Geyter C, Imthurn B, Lamy O, Litschgi M, Luzuy F, Schiessl K, Stute P, Birkhäuser M.

Eur Spine J. 2012 Dec;21(12):2407-17. doi: 10.1007/s00586-012-2404-y. Epub 2012 Jun 28. Review.

6.

Raloxifene: a review of its use in the prevention of invasive breast cancer.

Moen MD, Keating GM.

Drugs. 2008;68(14):2059-83. Review.

PMID:
18778124
7.

Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.

Pickar JH, Komm BS.

Post Reprod Health. 2015 Sep;21(3):112-21. doi: 10.1177/2053369115599090. Epub 2015 Aug 19. Review.

PMID:
26289836
8.

Raloxifene for older women: a review of the literature.

Hansdóttir H.

Clin Interv Aging. 2008;3(1):45-50. Review.

9.

Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.

Lewiecki EM.

J Womens Health (Larchmt). 2009 Oct;18(10):1615-26. doi: 10.1089/jwh.2008.1086. Review.

PMID:
19857095
10.
11.

Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.

Jordan VC, Gapstur S, Morrow M.

J Natl Cancer Inst. 2001 Oct 3;93(19):1449-57. Review.

PMID:
11584060
12.

Raloxifene: a review of its use in postmenopausal osteoporosis.

Clemett D, Spencer CM.

Drugs. 2000 Aug;60(2):379-411. Review.

PMID:
10983739
13.

Use of SERMs for treatment in postmenopausal women.

Pinkerton JV, Thomas S.

J Steroid Biochem Mol Biol. 2014 Jul;142:142-54. doi: 10.1016/j.jsbmb.2013.12.011. Epub 2013 Dec 25. Review.

PMID:
24373794
14.

Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.

Palacios S.

Curr Med Res Opin. 2010 Jul;26(7):1553-63. doi: 10.1185/03007991003795873. Review.

PMID:
20429824
15.

[Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient].

Kastelan D, Korsić M.

Reumatizam. 2005;52(2):67-70. Review. Croatian.

PMID:
16689133
16.

Prevention and treatment of osteoporosis in women with breast cancer.

Mincey BA, Moraghan TJ, Perez EA.

Mayo Clin Proc. 2000 Aug;75(8):821-9. Review. Erratum in: Mayo Clin Proc 2001 Jan;76(1):113.

PMID:
10943237
17.

The evolution of selective estrogen receptor modulators in osteoporosis therapy.

Hadji P.

Climacteric. 2012 Dec;15(6):513-23. doi: 10.3109/13697137.2012.688079. Epub 2012 Aug 1. Review.

18.

Chemoprevention of breast cancer: implications for postmenopausal women.

Fabian CJ, Kimler BF.

Drugs Aging. 2002;19(1):43-78. Review.

PMID:
11929326
19.

The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice.

Maximov PY, Lee TM, Jordan VC.

Curr Clin Pharmacol. 2013 May;8(2):135-55. Review.

20.

[Selective estrogen-receptor modulators (SERM's) in postmenopausal women].

Hart W, Netelenbos JC.

Ned Tijdschr Geneeskd. 1999 Aug 28;143(35):1771-6. Review. Dutch.

PMID:
10494328

Supplemental Content

Support Center